EC Number   |
Inhibitors |
Structure |
|---|
   2.7.11.30 | 2-bromo-2-(6-ethylpyridin-2-yl)-1-quinoxalin-6-ylethanone |
- |
   |
| 2.7.11.30 | 2-bromo-2-(6-methylpyridin-2-yl)-1-quinoxalin-6-ylethanone |
- |
|
| 2.7.11.30 | 2-bromo-2-pyridin-2-yl-1-quinoxalin-6-ylethanone |
- |
|
| 2.7.11.30 | 2-picoline |
- |
|
| 2.7.11.30 | 2-pyridin-2-yl-1-quinoxalin-6-ylethanone |
- |
|
| 2.7.11.30 | 3-((4-(6-methylpyridin-2-yl)-5-(quinolin-6-yl)-1H-imidazol-2-yl)methyl)benzamide |
IN-1233, inhibitor specifically inhibits TGF-beta signaling via ALK-5 by acting as a competitive inhibitor of the ATP-binding site, inhibition of activin receptor-like kinase-5 signaling in vivo with the selective small-molecule inhibitor prevents pulmonary arterial hypertension, right ventricular hypertrophy, and vascular remodeling after monocrotaline injection and inhibits the progression of established pulmonary arterial hypertension in this model |
|
| 2.7.11.30 | 3-([[4-(1,3-benzodioxol-5-yl)-5-(6-ethylpyridin-2-yl)-1,3-thiazol-2-yl]amino]methyl)benzamide |
- |
|
| 2.7.11.30 | 3-([[4-(1,3-benzodioxol-5-yl)-5-(6-ethylpyridin-2-yl)-1,3-thiazol-2-yl]amino]methyl)benzonitrile |
- |
|
| 2.7.11.30 | 3-([[4-(1,3-benzodioxol-5-yl)-5-(6-methylpyridin-2-yl)-1,3-thiazol-2-yl]amino]methyl)benzamide |
- |
|
| 2.7.11.30 | 3-([[4-(1,3-benzodioxol-5-yl)-5-(6-methylpyridin-2-yl)-1,3-thiazol-2-yl]amino]methyl)benzonitrile |
- |
|
